Kliogest

Norethisterone acetate and estradiol, the active ingredients in Kliogest, are combined estrogen‑progestogen agents presented as oral tablets for systemic use. They prevent pregnancy and help regulate menstrual cycles in women of reproductive age.

GNH USA supplies Kliogest as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kliogest is a combined estrogen‑progestogen oral contraceptive that acts on the hypothalamic‑pituitary‑ovarian axis. - Contraception: provides reliable prevention of pregnancy in women of reproductive age. - Menstrual cycle regulation: stabilises cycle length, reduces irregular bleeding and alleviates dysmenorrhoea.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Breast tenderness: discomfort or swelling of the breasts. - Headache: intermittent mild to moderate pain. - Spotting: irregular light bleeding between periods.

Serious or Rare Side Effects: - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism. - Hypertension: significant increase in blood pressure. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Liver dysfunction: jaundice or abnormal liver enzymes. - Stroke or visual disturbances: sudden loss of vision or neurological deficits.

Before prescribing Kliogest, clinicians should evaluate individual risk factors and counsel patients appropriately. - Assess thromboembolic risk: avoid in women with a history of clotting disorders. - Monitor blood pressure: contraindicated in uncontrolled hypertension. - Review liver function: use with caution in hepatic impairment. - Advise against smoking: especially for women over 35 years. - Avoid use in pregnancy: product is contraindicated (Category X). - Store at room temperature: keep in original packaging, protect from moisture and light.

Kliogest may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce contraceptive effect. - Anticoagulants (e.g., warfarin): may increase risk of clotting complications. - Certain antiepileptics (e.g., phenytoin): can diminish hormonal protection.

Moderate Interactions (Monitor Closely): - Antifungal agents (e.g., ketoconazole): may increase hormone levels. - Macrolide antibiotics (e.g., erythromycin): potential modest increase in plasma concentration. - Herbal supplements (e.g., St. John’s wort): may lower effectiveness of contraception.